Correct stimulation of CD28H arms NK cells against tumor cells.
Raphaëlle LeauPierre DuplouyeVirginie HuchetVéronique Nerrière-DaguinBernard MartinetMélanie NéelMartin MorinRichard DangerCécile BraudeauRégis JosienGilles BlanchoFabienne HaspotPublished in: European journal of immunology (2024)
Tumor evasion has recently been associated with a novel member of the B7 family, HERV-H LTR-associating 2 (HHLA2), which is mostly overexpressed in PDL-1 neg tumors. HHLA2 can either induce a costimulation signal when bound to CD28H or inhibit it by binding to KIR3DL3 on T- and NK cells. Given the broad distribution of CD28H expression on NK cells and its role, we compared two monoclonal antibodies targeting this novel NK-cell engager in this study. We show that targeting CD28H at a specific epitope not only strongly activates Ca 2+ flux but also results in NK-cell activation. CD28H-activated NK cells further display increased cytotoxic activity against hematopoietic cell lines and bypass HHLA2 and HLA-E inhibitory signals. Additionally, scRNA-seq analysis of clear cell renal cancer cells revealed that HHLA2 + clear cell renal cancer cell tumors were infiltrated with CD28H + NK cells, which could be targeted by finely chosen anti-CD28H Abs.